|
Video: What is a Stock Split?
|
|
Aravive is a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of diseases, including cancer and fibrosis. Co.'s primary product candidate, batiraxcept, is a decoy protein that targets the GAS6-AXL signaling pathway. By capturing serum GAS6, batiraxcept starves the AXL pathway of its signal, potentially halting the biological programming that promotes disease progression. AXL receptor signaling plays a role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression. According to our ARAV split history records, Aravive has had 1 split. | |
|
Aravive (ARAV) has 1 split in our ARAV split history database. The split for ARAV took place on October 16, 2018. This was a 1 for 6 reverse split, meaning for each 6 shares of ARAV owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split.
When a company such as Aravive conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ARAV split history from start to finish, an original position size of 1000 shares would have turned into 166.666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Aravive shares, starting with a $10,000 purchase of ARAV, presented on a split-history-adjusted basis factoring in the complete ARAV split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/10/2014 |
|
End date: |
02/05/2024 |
|
Start price/share: |
$118.74 |
|
End price/share: |
$0.04 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.97% |
|
Average Annual Total Return: |
-57.56% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$3.37 |
|
Years: |
9.33 |
|
|
|
Date |
Ratio |
10/16/2018 | 1 for 6 |
|
|